Clinical trial
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis…
NCT00358293 · Teva GTC, Industry · Completed
Key facts
| NCT number | NCT00358293 |
|---|---|
| Title | Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity |
| Official title | A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients |
| Lead sponsor | Teva GTC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Muscle Spasticity |
| Intervention type | Drug |
| Interventions | Tizanidine (sublingual or oral) |
| Enrollment | 20 |
| Start date | Dec 1, 2006 |
| Completion | Feb 1, 2007 |
| First posted | Jul 31, 2006 |
| Last update posted | Jan 21, 2009 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: